Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN PF 10 versus EPANOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN PF 10 versus EPANOVA.
AMINOSYN-PF 10% vs EPANOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-PF 10% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in neonates and pediatric patients.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Intravenous infusion: 1-1.5 g amino acids/kg/day (protein equivalent) as part of total parenteral nutrition. Typical rate: 0.5-2.0 mL/kg/hour initially, titrated to metabolic needs.
4 g orally once daily as 4 capsules of 1 g each with food.
None Documented
None Documented
Variable; amino acids have half-lives of minutes to hours; clinical context: continuous infusion maintains steady state
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Renal: >90% as amino acids and metabolites; <10% fecal/biliary
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution